Themis Bioscience Revenue and Competitors
Estimated Revenue & Valuation
- Themis Bioscience's estimated annual revenue is currently $4.8M per year.
- Themis Bioscience's estimated revenue per employee is $104,000
Employee Data
- Themis Bioscience has 46 Employees.
- Themis Bioscience grew their employee count by 2% last year.
Themis Bioscience's People
| Name | Title | Email/Phone |
|---|
Themis Bioscience Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.7M | 26 | -4% | $15.7M | N/A |
#2 | $1.4M | 21 | -50% | $21.2M | N/A |
#3 | $41.9M | 293 | 8% | $6M | N/A |
#4 | $6M | 53 | -22% | $216.8M | N/A |
#5 | $0M | 2 | 0% | $33.3M | N/A |
#6 | $26M | 182 | 0% | N/A | N/A |
#7 | $30.9M | 221 | -26% | $64.6M | N/A |
#8 | $28.6M | 205 | -22% | $46.8M | N/A |
#9 | $249.1M | 1340 | 15% | $75M | N/A |
#10 | $12.4M | 95 | 3% | N/A | N/A |
What Is Themis Bioscience?
Themis Bioscience is an international biotech company that successfully develops vaccines against emerging and specialist indications. Exploiting the full potential of our proprietary Themaxyn® platform we are able to identify and rapidly advance vaccine candidates at various stages of development. Based on a well-proven base technology, the Themaxyn® platform offers both, an excellent safety profile and a validated manufacturing process. Themis Bioscience was founded in 2009 by a group of internationally renowned vaccine and biotech executives in Vienna, Austria. In 2014 Themis successfully completed a phase I clinical trial with our Chikungunya vaccine in Austria. Themis continues to head the race for preventing emerging infectious diseases and started a phase II clinical trial with our Chikungunya vaccine in 2016 and a phase I clinical trial with our Zika vaccine in 2017.
keywords:N/A
N/A
Total Funding
46
Number of Employees
$4.8M
Revenue (est)
2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Themis Bioscience News
... And Forecast | Emergent BioSolutions, Valneva, Moderna, Novavax, Johnson & Johnson, Themis Bioscience, Sanofi, IMV, Takeda Pharmaceutical, CaroGen.
iBio; Themis Bioscience; Arbovax; Janssen Yellow Fever Treatment Market Breakdown by Type: Vaccine; Oral Rehydration; Pain Management...
As an executive, I have built companies like Nabriva, Themis Bioscience, and PDC Biotech. Phil Morle and his 4 No-Go's. He is a Partner at the...
Other Companies in Vienna
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.8M | 46 | -4% | N/A |
#2 | $7.7M | 46 | 7% | N/A |
#3 | $5.9M | 46 | -49% | N/A |
#4 | N/A | 46 | 59% | N/A |
#5 | $3.5M | 47 | 12% | N/A |